您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Dibutyryl-cAMP(Bucladesine sodium)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Dibutyryl-cAMP(Bucladesine sodium)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Dibutyryl-cAMP(Bucladesine sodium)图片
CAS NO:16980-89-5
规格:≥98%
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议
1g电议
5g电议
10g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)491.37
FormulaC18H23N5NaO8P
CAS No.16980-89-5 (Bucladesine sodium);
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 98 mg/mL (199.4 mM)
Water: 98 mg/mL (199.4 mM)
Ethanol: N/A
Solubility (In vivo)10% DMSO+ddH2O: 30 mg/mL
Synonyms

dbcAMP; DC-2797; Dibutyryl-cAMP sodium salt; DC2797; Sodium dibutyryl cAMP; DC 2797; Bucladesine sodium; DbcAMP sodium; Actosin; Sodium Dibutyryl cAMP; Cyclic dibutyryl-AMP sodium salt

Chemical Name: sodium (4aR,6R,7R,7aR)-6-(6-butyramido-9H-purin-9-yl)-7-(butyryloxy)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-olate 2-oxide

SMILES Code: O=P1(OC[C@H]2O[C@H]([C@@H]([C@@H]2O1)OC(CCC)=O)N3C4=NC=NC(NC(CCC)=O)=C4N=C3)[O-].[Na+]

实验参考方法
In Vitro

In vitro activity: Bucladesine sodium (also known as Dibutyryl-cAMP) is a cell-permeable PKA activator and a cAMP analog that mimics the action of endogenous cAMP. It is a cyclic nucleotide derivative (structurally similar to cAMP) and is also a phosphodiesterase inhibitor. Dibutyryl-cAMP preferentially activates cAMP-dependent protein kinase. The products releaes butyrate due to intracellular and extracellular esterase action. Butyrate was shown to have distinct biological effects. The compound is used in a wide variety of research applications because it mimics cAMP and can induce normal physiological responses when added to cells in experimental conditions.


Kinase Assay: Bucladesine sodium (also known as Dibutyryl-cAMP) is a cell-permeable PKA activator and a cAMP analog that mimics the action of endogenous cAMP. It is a cyclic nucleotide derivative (structurally similar to cAMP) and is also a phosphodiesterase inhibitor. Dibutyryl-cAMP preferentially activates cAMP-dependent protein kinase.

In VivoExperimentally naive male Albino Swiss mice (Laboratory Animals Breeding, Slaboszów, Poland) weighing 20–30 g were used in all experiments. The animals were housed in polycarbonate cages at a controlled temperature (23–25°C) and humidity (50–60%) with 12 h light/dark cycle (lights on at 6 h). Tap water and food pellets were available ad libitum. All experiments were performed after at least 7 days of acclimatization. The experimental protocols were approved by the Ethical Committee of the Medical University in Lublin (license number 40/2010). To allow for skin penetration of the cream formulations and based on preliminary experiments with ketoprofen cream in this model (data not presented), a pre-treatment time of 3 h was selected. To evaluate the effect of 0.5 or 1.5% bucladesine cream, an amount of 10 ± 1 mg cream each was spread onto the outer surface of both, left and right ears using small spatula. A third group of mice was administered with 2.5% ketoprofen gel. Corresponding vehicle treatment groups were administered either the respective cream base without bucladesine or, as reference for ketoprofen, a cosmetic night cream. To evaluate the effect of repeated administration, four separate groups of mice were dosed twice, i.e., 7 and 3 h before administration of arachidonic acid with the 0.5 and 1.5% cream or corresponding vehicle. Arachidonic acid or actetone were administered 3 h after the second cream administration onto left and right ears, respectively. The ear thickness was measured with a precise spring-loaded caliper (Mitutoyo, type 7309, Kawasaki, Japan) before and 60 min after application of arachidonic acid or vehicle.
Animal modelNaive male Albino Swiss mice
Formulation & DosageFor topical administration of bucladesine as 5% solution, 20 μl of drug or vehicle solution was administered onto the outer surface of both, left and right ears each, 60 min prior to arachidonic acid challenge. The inflammatory response was induced by administration of 20 μl arachidonic acid (Sigma-Aldrich, Munich, Germany; 5% in acetone) on the outer surface of left ears. The right ears were treated with acetone only to determine the individual differences in ear thicknesses.
References Arch Dermatol Res. 2012 May;304(4):313-7.